Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Avacta Group plc ( (GB:AVCT) ) has shared an announcement.
Avacta Group plc has completed the Phase 1a Dose Escalation and Recommended Dose for Expansion cohort of the AVA6000 trial and has opened enrollment for Phase 1b disease-specific expansion cohorts. These cohorts will focus on triple negative breast cancer, salivary gland cancer, and high-grade soft tissue sarcoma, building on promising preliminary results showing a favorable safety profile and significant antitumor activity. This development marks a significant milestone in the progression of AVA6000, a leading candidate in their innovative pre|CISION® platform targeting cancer treatments, potentially enhancing Avacta’s position in the life sciences industry.
More about Avacta Group plc
Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Its clinical stage oncology biotech division, Avacta Therapeutics, utilizes the proprietary pre|CISION® platform technology to develop novel cancer drugs, while Avacta Diagnostics aims to support healthcare professionals and enhance access to diagnostics.
YTD Price Performance: -62.45%
Average Trading Volume: 2,056,955
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £160.1M
Learn more about AVCT stock on TipRanks’ Stock Analysis page.
